{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:31:46Z","timestamp":1791477106383,"version":"4.3.4"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40265-021-01610-1","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T10:03:43Z","timestamp":1635329023000},"page":"1859-1879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-0313","authenticated-orcid":false,"given":"Eduardo","family":"Mysler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-388X","authenticated-orcid":false,"given":"Valderilio Feij\u00f3","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5541-9314","authenticated-orcid":false,"given":"Noriko","family":"Iikuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"issue":"6","key":"1610_CR1","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.semarthrit.2020.02.007","volume":"50","author":"A Lauret","year":"2020","unstructured":"Lauret A, Molto A, Abitbol V, Gutermann L, Conort O, Chast F, et al. Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. Semin Arthritis Rheum. 2020;50(6):1449\u201356.","journal-title":"Semin Arthritis Rheum"},{"key":"1610_CR2","unstructured":"Thomas L. Biosimilars: providing more treatment options. 2019. https:\/\/www.bio-rad.com\/webroot\/web\/pdf\/lsr\/literature\/Bulletin_7071.pdf. Accessed 5 Nov 2019."},{"key":"1610_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/BTT.S236433","volume":"14","author":"E Al Sulais","year":"2020","unstructured":"Al Sulais E, AlAmeel T. Biosimilars to antitumor necrosis factor agents in inflammatory bowel disease. Biologics Targets Therapy. 2020;14:1\u201311.","journal-title":"Biologics Targets Therapy."},{"issue":"2","key":"1610_CR4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","volume":"80","author":"H Kim","year":"2020","unstructured":"Kim H, Alten R, Avedano L, Dignass A, Gomollon F, Greveson K, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80(2):99\u2013113.","journal-title":"Drugs"},{"issue":"2","key":"1610_CR5","first-page":"54","volume":"44","author":"J Smeeding","year":"2019","unstructured":"Smeeding J, Malone DC, Ramchandani M, Stolshek B, Green L, Schneider P. Biosimilars: considerations for payers. P&T Peer-Rev J Formul Manage. 2019;44(2):54\u201363.","journal-title":"P&T Peer-Rev J Formul Manage"},{"key":"1610_CR6","first-page":"1","volume":"12","author":"\u00c1 Milassin","year":"2019","unstructured":"Milassin \u00c1, F\u00e1bi\u00e1n A, Moln\u00e1r T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therep Adv Gastroenterol. 2019;12:1\u201311.","journal-title":"Therep Adv Gastroenterol."},{"issue":"5","key":"1610_CR7","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s10067-019-04549-7","volume":"38","author":"RJ Moots","year":"2019","unstructured":"Moots RJ. Biosimilars in the Americas: the future by consensus. Clin Rheumatol. 2019;38(5):1497\u20139.","journal-title":"Clin Rheumatol"},{"key":"1610_CR8","unstructured":"US Food and Drug Administration. Advancing health through innovation. New drug therapy approvals 2019. 2020. https:\/\/www.fda.gov\/media\/134493\/download. Accessed 20 Mar 2020."},{"key":"1610_CR9","unstructured":"European Medicines Agency, European Commission. Biosimilars in the EU. Information guide for healthcare professionals. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 5 Aug 2019."},{"issue":"2","key":"1610_CR10","first-page":"138","volume":"29","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Norms and standards. Biotherapeutics and biosimilars. WHO Drug Infomation. 2015;29(2):138\u201341.","journal-title":"WHO Drug Infomation"},{"issue":"3","key":"1610_CR11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.rdc.2019.04.001","volume":"45","author":"J Kay","year":"2019","unstructured":"Kay J. Are there benefits and risks to biosimilars from a patient perspective? Rheum Dis Clin North Am. 2019;45(3):465\u201376.","journal-title":"Rheum Dis Clin North Am"},{"key":"1610_CR12","unstructured":"US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015. https:\/\/www.fda.gov\/media\/82647\/download. Accessed 4 Mar 2020."},{"key":"1610_CR13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.biologicals.2019.11.002","volume":"63","author":"PR van der Martijn","year":"2020","unstructured":"van der Martijn PR, Hoefnagel MHN, Hillege HL, Roes KCB. Pragmatic rules for comparability of biological medicinal products. Biologicals. 2020;63:97\u2013100.","journal-title":"Biologicals"},{"key":"1610_CR14","first-page":"38","volume":"2015","author":"J Sackman","year":"2015","unstructured":"Sackman J, Kuchenreuther M. The bullish outlook for biosimilars. BioPharm Int. 2015;2015:38\u201341.","journal-title":"BioPharm Int"},{"key":"1610_CR15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40259-019-00395-w","volume":"34","author":"B Dutta","year":"2020","unstructured":"Dutta B, Huys I, Vulto AG, Simoens S. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2020;34:159\u201370.","journal-title":"BioDrugs"},{"issue":"3","key":"1610_CR16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjd.16890","volume":"179","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Lacour JP, Fowler JF Jr, Weinberg JM, Gospodinov D, Schuck E, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623\u201331.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1610_CR17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","volume":"76","author":"W Park","year":"2017","unstructured":"Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Ure\u00f1a S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1610_CR18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","volume":"76","author":"DH Yoo","year":"2017","unstructured":"Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1610_CR19","doi-asserted-by":"crossref","first-page":"e000710","DOI":"10.1136\/rmdopen-2018-000710","volume":"4","author":"B Glintborg","year":"2018","unstructured":"Glintborg B, Sorensen J, Hetland ML. Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. RMD Open. 2018;4(2):e000710.","journal-title":"RMD Open"},{"issue":"1","key":"1610_CR20","doi-asserted-by":"crossref","first-page":"1705120","DOI":"10.1080\/20016689.2019.1705120","volume":"8","author":"S Simoens","year":"2020","unstructured":"Simoens S, Cheung R. Tendering and biosimilars: what role for value-added services? J Mark Access Health Policy. 2020;8(1):1705120.","journal-title":"J Mark Access Health Policy."},{"key":"1610_CR21","unstructured":"World Health Organization. Application to add anti-TNFs to the World Health Organization\u2019s essential medicines list. 2021. https:\/\/www.who.int\/selection_medicines\/committees\/expert\/22\/applications\/s8.1_TNF-alfa-inhibitors.pdf. Accessed 6 Jul 2021."},{"key":"1610_CR22","unstructured":"Allocati E, Gerardi C. Outcomes of switching from anti-tnf biologic drugs to their biosimilars: a systematic review. Final report November 2020. 2020. https:\/\/cdn.who.int\/media\/docs\/default-source\/essential-medicines\/2021-eml-expert-committee\/other-matters\/o.7_switching-anti-tnf.pdf?sfvrsn=ddae8024_6. Accessed 7 Jul 2020."},{"key":"1610_CR23","unstructured":"Mehr S. When biosimilars are switched for each other. 2019. https:\/\/biosimilarsrr.com\/2019\/05\/23\/when-biosimilars-are-switched-for-each-other\/. Accessed 20 Sep 2020."},{"issue":"1","key":"1610_CR24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.33590\/emjrheumatol\/10311746","volume":"5","author":"FC Ara\u00fajo","year":"2018","unstructured":"Ara\u00fajo FC, Fonseca JE, Goncalves J. Switching to biosimilars in inflammatory rheumatic conditions: current knowledge. EMJ Rheumatol. 2018;5(1):66\u201374.","journal-title":"EMJ Rheumatol."},{"issue":"9","key":"1610_CR25","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s12325-018-0742-9","volume":"35","author":"S Numan","year":"2018","unstructured":"Numan S, Faccin F. Non-medical switching from originator tumor necrosis factor inhibitors to their biosimilars: systematic review of randomized controlled trials and real-world studies. Adv Ther. 2018;35(9):1295\u2013332.","journal-title":"Adv Ther"},{"issue":"1","key":"1610_CR26","first-page":"34","volume":"4","author":"J Isaacs","year":"2017","unstructured":"Isaacs J, Goll GL, Goncalves J, Bosworth A. Biosimilars and switching: what is your perspective? EMJ Rheumatol. 2017;4(1):34\u201341.","journal-title":"EMJ Rheumatol."},{"issue":"1","key":"1610_CR27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2015-208113","volume":"76","author":"J Kay","year":"2017","unstructured":"Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis. 2017;76(1):4\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1610_CR28","unstructured":"Lai Z, La Noce A. Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example. 2018. https:\/\/www.syneoshealth.com\/sites\/default\/files\/documents\/53424_voinv_48_key_design_considerations_case_study_lo4.pdf. Accessed 27 Mar 2020."},{"key":"1610_CR29","doi-asserted-by":"crossref","first-page":"175628481985253","DOI":"10.1177\/1756284819852535","volume":"12","author":"JE McClellan","year":"2019","unstructured":"McClellan JE, Conlon HD, Bolt MW, Kalfayan V, Palaparthy R, Rehman MI, et al. The \u201ctotality-of-the-evidence\u201d approach in the development of PF-06438179\/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product. Therap Adv Gastroenterol. 2019;12:1756284819852535.","journal-title":"Therap Adv Gastroenterol."},{"issue":"21 Suppl","key":"1610_CR30","first-page":"S451","volume":"24","author":"V Bhatt","year":"2018","unstructured":"Bhatt V. Current market and regulatory landscape of biosimilars. Am J Manag Care. 2018;24(21 Suppl):S451\u20136.","journal-title":"Am J Manag Care"},{"issue":"10","key":"1610_CR31","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.19.02953","volume":"38","author":"J Stebbing","year":"2020","unstructured":"Stebbing J, Mainwaring PN, Curigliano G, Pegram M, Latymer M, Bair AH, et al. Understanding the role of comparative clinical studies in the development of oncology biosimilars. J Clin Oncol. 2020;38(10):1070\u201380.","journal-title":"J Clin Oncol"},{"key":"1610_CR32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/conmed-2017-100005","volume":"1","author":"V Azevedo","year":"2017","unstructured":"Azevedo V, D\u00f6rner T, Strohal R, Isaacs J, Casta\u00f1eda-Hern\u00e1ndez G, Gon\u00e7alves J, et al. Biosimilars: considerations for clinical practice. Considerations Med. 2017;1:13\u20138.","journal-title":"Considerations Med."},{"key":"1610_CR33","unstructured":"Regional Medicines Optimisation Committee. Regional Medicines Optimisation Committee briefing best value biologicals: adalimumab update 6. 2019. https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2019\/07\/Adalimumab-RMOC-Briefing-6.pdf. Accessed 19 Mar 2020."},{"key":"1610_CR34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/psb.1773","volume":"2019","author":"S Houlton","year":"2019","unstructured":"Houlton S. Benefits and drawbacks of moving to biosimilar medicines. Prescriber. 2019;2019:13\u20135.","journal-title":"Prescriber"},{"key":"1610_CR35","unstructured":"Erskine D, Minshull J. Update on development of biosimilar versions of adalimumab with particular focus on excipients and injection site reactions 2019. https:\/\/www.sps.nhs.uk\/articles\/update-on-development-of-biosimilar-versions-of-adalimumab-with-particular-focus-on-excipients-and-injection-site-reactions\/. Accessed 4 Oct 2021."},{"issue":"2","key":"1610_CR36","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40744-018-0119-1","volume":"5","author":"S Ramael","year":"2018","unstructured":"Ramael S, Van Hoorick B, Tiessen R, van Iersel T, Moschetti V, Lang B, et al. Similar pharmacokinetics of the adalimumab (Humira\u00ae) Biosimilar BI 695501 whether administered via subcutaneous autoinjector or prefilled syringe (VOLTAIRE\u00ae)-AI and VOLTAIRE\u00ae-TAI): phase 1, randomized, open-label, parallel-group trials. Rheumatol Ther. 2018;5(2):403\u201321.","journal-title":"Rheumatol Ther."},{"key":"1610_CR37","unstructured":"Sandoz Inc. ZARXIO\u00ae (filgrastim-sndz) prescribing information. 2019. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c0d1c22b-566b-4776-bdbf-00f96dad0cae. Accessed 22 Feb 2021."},{"key":"1610_CR38","unstructured":"Hospira, Inc. (a Pfizer Company). NIVESTYM\u2122 (filgrastim-aafi) prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761080s000lbl.pdf Accessed Feb 2021."},{"issue":"2","key":"1610_CR39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/RHU.0000000000000881","volume":"25","author":"VF Azevedo","year":"2019","unstructured":"Azevedo VF, Babini A, Caballero-Uribe CV, Casta\u00f1eda-Hern\u00e1ndez G, Borlenghi C, Jones HE. Practical guidance on biosimilars, with a focus on Latin America: what do rheumatologists need to know? J Clin Rheumatol. 2019;25(2):91\u2013100.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"1610_CR40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.40388","volume":"70","author":"SL Bridges Jr","year":"2018","unstructured":"Bridges SL Jr, White DW, Worthing AB, Gravallese EM, O\u2019Dell JR, Nola K, et al. The science behind biosimilars: entering a new era of biologic therapy. Arthritis Rheumatol. 2018;70(3):334\u201344.","journal-title":"Arthritis Rheumatol"},{"key":"1610_CR41","unstructured":"The Alliance for Safe Biologic Medicines (ASBM). Non-medical switching. 2020. https:\/\/safebiologics.org\/non-medical-switching\/ Accessed 13 Mar 2020."},{"key":"1610_CR42","unstructured":"Mehr S. What happens when switching among biosimilars. 2017. https:\/\/biosimilarsrr.com\/2017\/06\/20\/what-happens-when-switching-among-biosimilars\/ Accessed 13 Mar 2020."},{"issue":"9","key":"1610_CR43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1310\/hpj4909-813","volume":"49","author":"N Griffith","year":"2014","unstructured":"Griffith N, McBride A, Stevenson JG, Green L. Formulary selection criteria for biosimilars: considerations for US health-system pharmacists. Hosp Pharm. 2014;49(9):813\u201325.","journal-title":"Hosp Pharm"},{"key":"1610_CR44","unstructured":"Kim M, Monnard A, da Silva JS. Understanding the opportunity in Japan's biosimilar market. 2019. https:\/\/www.mckinsey.com\/\/media\/McKinsey\/Industries\/Pharmaceuticals%20and%20Medical%20Products\/Our%20Insights\/Understanding%20the%20opportunity%20in%20Japans%20biosimilar%20market\/Understanding-the-opportunity-in-Japans-biosimilar-market.pdf?shouldIndex=false. Accessed 18 Nov 2020."},{"key":"1610_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa364","author":"S Mahmmod","year":"2021","unstructured":"Mahmmod S, Schultheiss JPD, van Bodegraven AA, Dijkstra G, Gilissen LPL, Hoentjen F, et al. Outcome of reverse switching from CT-P13 to originator infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2021. https:\/\/doi.org\/10.1093\/ibd\/izaa364.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"1610_CR46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5639\/gabij.2017.0602.014","volume":"6","author":"A Roediger","year":"2017","unstructured":"Roediger A, Freischem B, Reiland J-B. What pricing and reimbursement policies to use for off-patent biologicals in Europe? Results from the second EBE biological medicines policy survey. GaBI J. 2017;6(2):61\u201378.","journal-title":"GaBI J."},{"key":"1610_CR47","unstructured":"Davio K. Switching among multiple infliximab biosimilars does not cause immunogenicity, study finds. 2019. https:\/\/www.centerforbiosimilars.com\/conferences\/eular-2019\/switching-among-multiple-infliximab-biosimilars-does-not-cause-immunogenicity-study-finds. Accessed 28 Jul 2020."},{"key":"1610_CR48","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5639\/gabij.2015.0402.018","volume":"4","author":"A Mack","year":"2015","unstructured":"Mack A. Norway, biosimilars in different funding systems. What works? GaBi J. 2015;4:90\u20132.","journal-title":"GaBi J."},{"key":"1610_CR49","unstructured":"Dylst P. The 2017 market review\u2014European biosimilar medicines markets\u2014policy overview. 2017. https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2017\/09\/Market-Review-biosimilar-medicines-market-2017.pdf. Accessed 22 Feb 2021."},{"key":"1610_CR50","doi-asserted-by":"publisher","DOI":"10.1177\/2168479019872144.2168479019872144","author":"A Singh","year":"2019","unstructured":"Singh A, Kalaivani M, Srivastava S, Goyal RK, Gupta SK. Postmarketing safety of biosimilars: current status, challenges, and opportunities in the spontaneous reporting system. Ther Innov Regul Sci. 2019. https:\/\/doi.org\/10.1177\/2168479019872144.2168479019872144.","journal-title":"Ther Innov Regul Sci."},{"key":"1610_CR51","unstructured":"Frapaise F-X. Biosimilars in the age of patient-centricity. GaBi Online. 2020. http:\/\/gabionline.net\/Biosimilars\/Research\/Biosimilars-in-the-age-of-patient-centricity. Accessed 20 Sep 2020."},{"key":"1610_CR52","unstructured":"Krant J. Biosimilar confidence: physician-patient communication sets the tone. 2017. https:\/\/www.rheumatologyadvisor.com\/home\/topics\/rheumatoid-arthritis\/biosimilar-confidence-physician-patient-communication-sets-the-tone\/. Accessed 19 Mar 2020."},{"issue":"8","key":"1610_CR53","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/17474124.2019.1645595","volume":"13","author":"L Peyrin-Biroulet","year":"2019","unstructured":"Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, et al. Anti-TNF biosimilars in Crohn\u2019s disease: a patient-centric interdisciplinary approach. Expert Rev Gastroenterol Hepatol. 2019;13(8):731\u20138.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"6","key":"1610_CR54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11926-017-0658-4","volume":"19","author":"R Moots","year":"2017","unstructured":"Moots R, Azevedo V, Coindreau JL, D\u00f6rner T, Mahgoub E, Mysler E, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep. 2017;19(6):37.","journal-title":"Curr Rheumatol Rep"},{"key":"1610_CR55","unstructured":"NHS England and NHS improvement. What is a biosimilar medicine? 2019. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2019\/05\/what-is-a-biosimilar-medicine-guide-v2.pdf. Accessed 19 Mar 2020."},{"key":"1610_CR56","unstructured":"GaBi Online. Switching approaches to biosimilars in Nordic countries. 2017. http:\/\/gabionline.net\/Reports\/Switching-approaches-to-biosimilars-in-Nordic-countries. Accessed 21 Sep 2020."},{"key":"1610_CR57","first-page":"7928","volume":"303","author":"J Robinson","year":"2019","unstructured":"Robinson J. Majority of patients not asked for consent before being switched to a biosimilar, survey finds. Pharma J. 2019;303:7928.","journal-title":"Pharma J."},{"key":"1610_CR58","unstructured":"GaBi Online. Biosimilars approved in Europe. 2020. http:\/\/www.gabionline.net\/Biosimilars\/General\/Biosimilars-approved-in-Europe. Accessed 21 Sep 2020."},{"key":"1610_CR59","unstructured":"AJMC: The Center for Biosimilars. Kathy Oubre: other players complicate biosimilar use for cancer centers. 2020. https:\/\/www.centerforbiosimilars.com\/interviews\/kathy-oubre-other-players-complicate-biosimilar-use-for-cancer-centers. Accessed 21 Sep 2020."},{"key":"1610_CR60","unstructured":"US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product. Guidance for industry. 2019. https:\/\/www.fda.gov\/media\/124907\/download. Accessed 19 Jun 2019."},{"key":"1610_CR61","unstructured":"US Food and Drug Administration. Biosimilar and interchangeable biologics: more treatment choices. 2020. https:\/\/www.fda.gov\/consumers\/consumer-updates\/biosimilar-and-interchangeable-biologics-more-treatment-choices. Accessed 27 Jul 2020."},{"key":"1610_CR62","unstructured":"GaBi Online. 45 US states have passed biosimilar substitution laws. 2017. http:\/\/gabionline.net\/Policies-Legislation\/45-US-states-have-passed-biosimilar-substitution-laws#:~:text=To%20date%2C%2045%20US%20states,and%20the%20District%20of%20Columbia. Accessed 21 Sep 2020."},{"key":"1610_CR63","unstructured":"US Food and Drug Administration. Prescribing biosimilar products. 2020. https:\/\/www.fda.gov\/media\/108103\/download. Accessed 27 Jul 2020."},{"issue":"4","key":"1610_CR64","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cpt.1310","volume":"105","author":"NS Vermeer","year":"2019","unstructured":"Vermeer NS, Giezen TJ, Zastavnik S, Wolff-Holz E, Hidalgo-Simon A. Identifiability of biologicals in adverse drug reaction reports received from European clinical practice. Clin Pharmacol Ther. 2019;105(4):962\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1610_CR65","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Product- or population-specific considerations II: biological medicinal products products. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-product-population-specific-considerations-ii_en-0.pdf. Accessed 7 Jul 2021."},{"key":"1610_CR66","unstructured":"GI Society: Canadian Society of Intestinal Research. Biologics and biosimilars. 2020. https:\/\/badgut.org\/information-centre\/a-z-digestive-topics\/biosimilars-pamphlet\/. Accessed 9 Mar 2020."},{"key":"1610_CR67","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrgastro.2016.155","volume":"14","author":"S Danese","year":"2017","unstructured":"Danese S, Bonovos S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017;14:22\u201331.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"1610_CR68","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s10620-019-05504-x","volume":"64","author":"C Le Berre","year":"2019","unstructured":"Le Berre C, Danese S, Peyrin-Biroulet L. Timely use of biologics in early Crohn\u2019s disease: the return of \u201chit hard and early\u201d? Digest Dis Sci. 2019;64(11):3035\u20137.","journal-title":"Digest Dis Sci."},{"issue":"1","key":"1610_CR69","doi-asserted-by":"crossref","first-page":"e0227960","DOI":"10.1371\/journal.pone.0227960","volume":"15","author":"YK Sung","year":"2020","unstructured":"Sung YK, Jung SY, Kim H, Choi S, Im SG, Lee YS, et al. Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world. PLoS ONE. 2020;15(1):e0227960.","journal-title":"PLoS ONE"},{"issue":"1","key":"1610_CR70","first-page":"102","volume":"25","author":"E Leonard","year":"2019","unstructured":"Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25(1):102\u201312.","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"1610_CR71","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/09546634.2019.1610553","volume":"31","author":"J Barker","year":"2020","unstructured":"Barker J, Girolomoni G, Egeberg A, Goncalves J, Pieper B, Kang T. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. J Dermatolog Treat. 2020;31(8):794\u2013800.","journal-title":"J Dermatolog Treat"},{"issue":"11","key":"1610_CR72","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3748\/wjg.v23.i11.1932","volume":"23","author":"MK Zheng","year":"2017","unstructured":"Zheng MK, Shih DQ, Chen GC. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol. 2017;23(11):1932\u201343.","journal-title":"World J Gastroenterol"},{"key":"1610_CR73","doi-asserted-by":"crossref","first-page":"S876","DOI":"10.1016\/S0016-5085(19)39159-0","volume":"156","author":"L Gonczi","year":"2019","unstructured":"Gonczi L, Ilias A, Szanto K, Kurti Z, Golovics PA, Farkas K, et al. Mo1892\u2014non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring. Gastroenterology. 2019;156:S876\u20137.","journal-title":"Gastroenterology"},{"key":"1610_CR74","unstructured":"Davio K. Switching back to reference infliximab from biosimilar appears effective for patients with IBD. 2019. https:\/\/www.centerforbiosimilars.com\/news\/switching-back-to-reference-infliximab-from-biosimilar-appears-effective-for-patients-with-ibd. Accessed 9 Mar 2020."},{"issue":"1","key":"1610_CR75","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/ecco-jcc\/jjw198","volume":"11","author":"S Danese","year":"2017","unstructured":"Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohns Colitis. 2017;11(1):26\u201334.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"1610_CR76","doi-asserted-by":"crossref","first-page":"e000492","DOI":"10.1136\/rmdopen-2017-000492","volume":"3","author":"E Toussirot","year":"2017","unstructured":"Toussirot E, Marotte H. Switching from originator biological agents to biosimilars: what is the evidence and what are the issues? RMD Open. 2017;3(2):e000492.","journal-title":"RMD Open"},{"issue":"9","key":"1610_CR77","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nrgastro.2017.86","volume":"14","author":"S Danese","year":"2017","unstructured":"Danese S, Peyrin-Biroulet L. IBD: to switch or not to switch: that is the biosimilar question. Nat Rev Gastroenterol Hepatol. 2017;14(9):508\u20139.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"1610_CR78","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/rheumatology\/kex277","volume":"56","author":"H Schulze-Koops","year":"2017","unstructured":"Schulze-Koops H, Skapenko A. Biosimilars in rheumatology: a review of the evidence and their place in the treatment algorithm. Rheumatol (Oxf). 2017;56(4 Suppl):iv30\u201348.","journal-title":"Rheumatol (Oxf)."},{"issue":"1","key":"1610_CR79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apt.14997","volume":"49","author":"BG Feagan","year":"2019","unstructured":"Feagan BG, Lam G, Ma C, Lichtenstein GR. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2019;49(1):31\u201340.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"1610_CR80","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14740338.2019.1602117","volume":"18","author":"G Murdaca","year":"2019","unstructured":"Murdaca G, Negrini S, Greco M, Schiavi C, Giusti F, Borro M, et al. Immunogenicity of infliximab and adalimumab. Expert Opin Drug Safety. 2019;18(5):343\u20135.","journal-title":"Expert Opin Drug Safety."},{"key":"1610_CR81","doi-asserted-by":"crossref","first-page":"175628481989108","DOI":"10.1177\/1756284819891081","volume":"12","author":"J Goncalves","year":"2019","unstructured":"Goncalves J, Myung G, Park M, Jeong D, Ghil J. SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis. Therap Adv Gastroenterol. 2019;12:1756284819891081.","journal-title":"Therap Adv Gastroenterol."},{"issue":"6","key":"1610_CR82","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.gastrohep.2018.04.005","volume":"41","author":"JP Gisbert","year":"2018","unstructured":"Gisbert JP, Chaparro M. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: can it be recommended? A systematic review. Gastroenterol Hepatol. 2018;41(6):389\u2013405.","journal-title":"Gastroenterol Hepatol"},{"issue":"6","key":"1610_CR83","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14712598.2018.1469620","volume":"18","author":"Z Kurti","year":"2018","unstructured":"Kurti Z, Gonczi L, Lakatos PL. Progress with infliximab biosimilars for inflammatory bowel disease. Expert Opin Biol Ther. 2018;18(6):633\u201340.","journal-title":"Expert Opin Biol Ther"},{"key":"1610_CR84","unstructured":"Chu R, Tortensson D, Pugatch M. Patient safety and comfort: the challenges of switching medicine. Stockholm Netw. 2010;2010."},{"key":"1610_CR85","unstructured":"Medicines for Europe. The total clinical experience with biosimilar medicines exceeds 2 billion patient treatment days. 2020. https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2020\/12\/BIOS5.pdf. Accessed 7 Jul 2021."},{"key":"1610_CR86","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.zefq.2018.12.001","volume":"140","author":"M Weise","year":"2019","unstructured":"Weise M. From bioequivalence to biosimilars: how much do regulators dare? Z Evid Fortbild Qual Gesundhwes. 2019;140:58\u201362.","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"issue":"1","key":"1610_CR87","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40259-015-0155-0","volume":"30","author":"C D\u2019Amore","year":"2016","unstructured":"D\u2019Amore C, Da Cas R, Rossi M, Traversa G. Switching between epoetins: a practice in support of biosimilar use. BioDrugs. 2016;30(1):27\u201332.","journal-title":"BioDrugs"},{"issue":"46","key":"1610_CR88","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.3748\/wjg.v24.i46.5288","volume":"24","author":"MF Guerra Veloz","year":"2018","unstructured":"Guerra Veloz MF, Arguelles-Arias F, Castro Laria L, Maldonado Perez B, Benitez Roldan A, Perea Amarillo R, et al. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol. 2018;24(46):5288\u201396.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1610_CR89","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bcp.12931","volume":"82","author":"T Arato","year":"2016","unstructured":"Arato T. Japanese regulation of biosimilar products: past experience and current challenges. Br J Clin Pharmacol. 2016;82(1):30\u201340.","journal-title":"Br J Clin Pharmacol"},{"key":"1610_CR90","unstructured":"Health Canada. Biosimilar biologic drugs. 2020. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/biosimilar-biologic-drugs.html. Accessed 18 Nov 2020."},{"key":"1610_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.09.006","author":"MC Bielsky","year":"2020","unstructured":"Bielsky MC, Cook A, Wallington A, Exley A, Kauser S, Hay JL, et al. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. Drug Discov Today. 2020. https:\/\/doi.org\/10.1016\/j.drudis.2020.09.006.","journal-title":"Drug Discov Today"},{"key":"1610_CR92","first-page":"1","volume":"8","author":"E Doevendans","year":"2019","unstructured":"Doevendans E, Schellekens H. Immunogenicity of innovative and biosimilar monoclonal antibodies. Antibodies (Basel). 2019;8(1).","journal-title":"Antibodies (Basel)."},{"key":"1610_CR93","unstructured":"Groopman J, Hartzband P. Framing risks, benefits perilous for physicians and patients. 2012. https:\/\/www.acpinternist.org\/archives\/2012\/01\/gray.htm. Accessed 11 Mar 2020."},{"issue":"5","key":"1610_CR94","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40259-019-00372-3","volume":"33","author":"CJ Webster","year":"2019","unstructured":"Webster CJ, Woollett GR. Comment on \u201cAnalysis of pharmacokinetic and pharmacodynamic parameters in EU-versus US-licensed reference biological products: are in vivo bridging studies justified for biosimilar development?\u201d BioDrugs. 2019;33(5):581\u20132.","journal-title":"BioDrugs"},{"issue":"4","key":"1610_CR95","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40259-019-00357-2","volume":"33","author":"C-L Tu","year":"2019","unstructured":"Tu C-L, Wang Y-L, Hu T-M, Hsu L-F. Analysis of pharmacokinetic and pharmacodynamic parameters in EU- versus US-licensed reference biological products: are in vivo bridging studies justified for biosimilar development? BioDrugs. 2019;33(4):437\u201346.","journal-title":"BioDrugs"},{"issue":"33","key":"1610_CR96","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40259-019-00371-4","volume":"06","author":"CJ Webster","year":"2019","unstructured":"Webster CJ, Wong AC, Woollett GR. An efficient development paradigm for biosimilars. BioDrugs. 2019;06(33):603\u201311.","journal-title":"BioDrugs"},{"issue":"3","key":"1610_CR97","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5639\/gabij.2015.0403.027","volume":"4","author":"TL Gerrard","year":"2015","unstructured":"Gerrard TL, Johnston G, Gaugh DR. Biosimilars: extrapolation of clinical use to other indications. GaBi J. 2015;4(3):118\u201324.","journal-title":"GaBi J."},{"issue":"3","key":"1610_CR98","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40259-017-0218-5","volume":"31","author":"R Markus","year":"2017","unstructured":"Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community. BioDrugs. 2017;31(3):175\u201387.","journal-title":"BioDrugs"},{"key":"1610_CR99","unstructured":"US Food and Drug Administration. Biosimilar and interchangeable products. 2017. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-and-interchangeable-products. Accessed 29 Sep 2019."},{"key":"1610_CR100","unstructured":"US Food and Drug Administration. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations. Guidance for industry [DRAFT GUIDANCE] 2019. https:\/\/www.fda.gov\/media\/125484\/download. Accessed 27 Mar 2020."},{"issue":"2","key":"1610_CR101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.31021\/ijbs.20181109","volume":"1","author":"J Yuan","year":"2018","unstructured":"Yuan J, Xu WW, Poon H. Analytical approach for biosimilar development: special focus on monoclonal antibody biosimilars. Int J Biopharm Sci. 2018;1(2):1\u20134.","journal-title":"Int J Biopharm Sci."},{"key":"1610_CR102","doi-asserted-by":"crossref","first-page":"104415","DOI":"10.1016\/j.yrtph.2019.104415","volume":"107","author":"P Pipalava","year":"2019","unstructured":"Pipalava P, Patel R, Mehta M, Dahiya M, Singh I, Jose V. An update on the animal studies conducted for biosimilar approvals\u2014regulatory requirement vs actual scenario. Regul Toxicol Pharmacol. 2019;107:104415.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"1610_CR103","doi-asserted-by":"crossref","first-page":"e1800340","DOI":"10.1002\/biot.201800340","volume":"14","author":"B Beyer","year":"2019","unstructured":"Beyer B, Walch N, Jungbauer A, Lingg N. How similar is biosimilar? A comparison of infliximab therapeutics in regard to charge variant profile and antigen binding affinity. Biotechnol J. 2019;14(4):e1800340.","journal-title":"Biotechnol J"},{"issue":"1","key":"1610_CR104","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/conmed-2017-100003","volume":"1","author":"J Isaacs","year":"2017","unstructured":"Isaacs J, Gon\u00e7alves J, Strohal R, Casta\u00f1eda-Hern\u00e1ndez G, Azevedo V, D\u00f6rner T, et al. The biosimilar approval process: how different is it? Considerations Med. 2017;1(1):3\u20136.","journal-title":"Considerations Med."},{"issue":"10086","key":"1610_CR105","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304\u201316.","journal-title":"Lancet"},{"issue":"4","key":"1610_CR106","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","volume":"78","author":"HP Cohen","year":"2018","unstructured":"Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463\u201378.","journal-title":"Drugs"},{"issue":"10","key":"1610_CR107","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.drudis.2019.06.016","volume":"24","author":"HC Ebbers","year":"2019","unstructured":"Ebbers HC, Schellekens H. Are we ready to close the discussion on the interchangeability of biosimilars? Drug Discov Today. 2019;24(10):1963\u20137.","journal-title":"Drug Discov Today"},{"issue":"5","key":"1610_CR108","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/jcag\/gwz044","volume":"3","author":"GG Kaplan","year":"2020","unstructured":"Kaplan GG, Ma C, Seow CH, Kroeker KI, Panaccione R. The argument against a biosimilar switch policy for infliximab in patients with inflammatory bowel disease living in Alberta. J Can Assoc Gastroenterol. 2020;3(5):234\u201342.","journal-title":"J Can Assoc Gastroenterol."},{"key":"1610_CR109","unstructured":"Davio K. An expert view on immunogenicity and biosimilars. 2019. https:\/\/www.centerforbiosimilars.com\/conferences\/biotech-pharma-summit-biosimilars\/an-expert-view-on-immunogenicity-and-biosimilars. Accessed 29 Jul 2020."},{"issue":"7","key":"1610_CR110","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/gutjnl-2015-309290","volume":"65","author":"S Ben-Horin","year":"2016","unstructured":"Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2016;65(7):1132\u20138.","journal-title":"Gut"},{"issue":"9","key":"1610_CR111","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/annrheumdis-2015-208684","volume":"75","author":"MB Ruiz-Arg\u00fcello","year":"2016","unstructured":"Ruiz-Arg\u00fcello MB, Maguregui A, del Ruiz AA, Pascual-Salcedo D, Mart\u00ednez-Feito A, Jurado T, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75(9):1693\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1610_CR112","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40259-017-0210-0","volume":"31","author":"P Kurki","year":"2017","unstructured":"Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31(2):83\u201391.","journal-title":"BioDrugs"},{"issue":"1","key":"1610_CR113","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13075-018-1676-y","volume":"20","author":"RM Fleischmann","year":"2018","unstructured":"Fleischmann RM, Alten R, Pileckyte M, Lobello K, Hua SY, Cronenberger C, et al. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira\u00ae) in the treatment of active rheumatoid arthritis. Arthritis Res Ther. 2018;20(1):178.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1610_CR114","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ibd\/izx086","volume":"24","author":"G Fiorino","year":"2018","unstructured":"Fiorino G, Ruiz-Arguello MB, Maguregui A, Nagore D, Correale C, Radice S, et al. Full interchangeability in regard to immunogenicity between the infliximab reference biologic and biosimilars CT-P13 and SB2 in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(3):601\u20136.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"1610_CR115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5217\/ir.2019.00026","volume":"17","author":"CJ Ooi","year":"2019","unstructured":"Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn\u2019s disease in Asia. Intest Res. 2019;17(3):285\u2013310.","journal-title":"Intest Res"},{"issue":"4","key":"1610_CR116","first-page":"414","volume":"83","author":"A Mayoral-Zavala","year":"2018","unstructured":"Mayoral-Zavala A, Esquivel-Aguilar A, Del Real-Calzada CM, Gutierrez-Grobe Y, Ramos-Garcia J, Rocha-Ramirez JL, et al. Update on biosimilars in inflammatory bowel disease: position and recommendations in Mexico. Rev Gastroenterol Mex. 2018;83(4):414\u201323.","journal-title":"Rev Gastroenterol Mex"},{"issue":"3","key":"1610_CR117","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","volume":"30","author":"C Pineda","year":"2016","unstructured":"Pineda C, Casta\u00f1eda Hern\u00e1ndez G, Jacobs IA, Alvarez DF, Carini C. Assessing the immunogenicity of biopharmaceuticals. BioDrugs. 2016;30(3):195\u2013206.","journal-title":"BioDrugs"},{"issue":"1","key":"1610_CR118","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40259-019-00394-x","volume":"34","author":"V Strand","year":"2020","unstructured":"Strand V, Gon\u00e7alves J, Hickling TP, Jones HE, Marshall L, Isaacs JD. Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents. BioDrugs. 2020;34(1):27\u201337.","journal-title":"BioDrugs"},{"issue":"1","key":"1610_CR119","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MPG.0000000000002141","volume":"68","author":"L de Ridder","year":"2019","unstructured":"de Ridder L, Assa A, Bronsky J, Romano C, Russell RK, Afzal NA, et al. Use of biosimilars in pediatric inflammatory bowel disease: an updated position statement of the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2019;68(1):144\u201353.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"1610_CR120","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.clinthera.2018.03.018","volume":"40","author":"P Declerck","year":"2018","unstructured":"Declerck P, Bakalos G, Zintzaras E, Barton B, Schreitm\u00fcller T. Monoclonal antibody biosimilars in oncology: critical appraisal of available data on switching. Clin Ther. 2018;40(5):798\u2013809.e2.","journal-title":"Clin Ther"},{"key":"1610_CR121","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/S1590-8658(19)30462-1","volume":"51","author":"R Lovero","year":"2019","unstructured":"Lovero R, Losurdo G, Biscaglia G, Valvano MR, Biancofiore A, Martino G, et al. P.07.13 Safety and efficacy of infliximab biosimilar SB2 in patients with inflammatory bowel disease who underwent a switch from infliximab biosimilar CT-P13. Dig Liver Dis. 2019;51:e227.","journal-title":"Dig Liver Dis"},{"issue":"8","key":"1610_CR122","first-page":"361","volume":"7","author":"C Harris","year":"2019","unstructured":"Harris C, Harris R, Young D, McDonnell M, Harvey J, Felwick R, et al. IBD biosimilar to biosimilar infliximab switching study: preliminary results. United Eur Gastroenterol J. 2019;7(8):361.","journal-title":"United Eur Gastroenterol J."},{"issue":"3 Suppl","key":"1610_CR123","first-page":"29","volume":"33","author":"P Gisondi","year":"2019","unstructured":"Gisondi P, Virga C, Girolomoni G. P049. Cross-switch from CT-P13 to SB2 infliximab biosimilars in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2019;33(3 Suppl):29.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1 Suppl","key":"1610_CR124","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1093\/ecco-jcc\/jjz203.489","volume":"14","author":"S Mazza","year":"2020","unstructured":"Mazza S, Fasc\u00ec A, Casini V, Ricci C, Munari F, Pirola LL, et al. P360 Safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS); a multicentre study. J Crohn\u2019s Colitis. 2020;14(1 Suppl):S342.","journal-title":"J Crohn's Colitis."},{"key":"1610_CR125","doi-asserted-by":"crossref","first-page":"S529","DOI":"10.1093\/ecco-jcc\/jjz203.765","volume":"14","author":"Y Bouhnik","year":"2020","unstructured":"Bouhnik Y, Fautrel B, Desjeux G, Freudensprung U, Brigui A, Addison J. P637 PERFUSE: a French non-intervential cohort study of infliximab-naive and trnasitioned patients receiving infliximab biosimilar SB2; an interim analysis. J Crohn\u2019s Colitis. 2020;14:S529.","journal-title":"J Crohn's Colitis"},{"key":"1610_CR126","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16497","author":"RP Luber","year":"2021","unstructured":"Luber RP, O\u2019Neill R, Singh S, Sharma E, Cunningham G, Honap S, et al. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Aliment Pharmacol Ther. 2021. https:\/\/doi.org\/10.1111\/apt.16497.","journal-title":"Aliment Pharmacol Ther"},{"key":"1610_CR127","unstructured":"Davio K. Switching to biosimilars in the NHS provides savings, presents unique challenges. 2018. https:\/\/www.centerforbiosimilars.com\/conferences\/smi-biosimilars\/switching-to-biosimilars-in-the-nhs-provides-savings-presents-unique-challenges. Accessed 16 Mar 2020."},{"key":"1610_CR128","doi-asserted-by":"crossref","first-page":"175628481879695","DOI":"10.1177\/1756284818796956","volume":"11","author":"F Magro","year":"2018","unstructured":"Magro F, Rocha C, Vieira AI, Sousa HT, Rosa I, Lopes S, et al. The performance of Remicade\u00ae-optimized quantification assays in the assessment of Flixabi\u00ae levels. Therap Adv Gastroenterol. 2018;11:1756284818796956.","journal-title":"Therap Adv Gastroenterol."},{"issue":"1 Suppl","key":"1610_CR129","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1093\/ecco-jcc\/jjx180.356","volume":"12","author":"F Magro","year":"2018","unstructured":"Magro F, Rocha C, Vieira AI, Sousa HT, Rosa I, Lopes I, et al. P229 The new biosimilar of infiximab SB2 can be quantifed by IFX-optimised therapeutic drug monitoring assays. J Crohn\u2019s Colitis. 2018;12(1 Suppl):S216.","journal-title":"J Crohn's Colitis."},{"issue":"2","key":"1610_CR130","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40259-019-00402-0","volume":"34","author":"HC Ebbers","year":"2020","unstructured":"Ebbers HC, Fehrmann B, Ottosen M, Hvorslev N, Hoier P, Hwang JW, et al. Batch-to-batch consistency of SB4 and SB2, etanercept and infliximab biosimilars. BioDrugs. 2020;34(2):225\u201333.","journal-title":"BioDrugs"},{"issue":"7","key":"1610_CR131","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/gutjnl-2013-305600","volume":"63","author":"K Bodger","year":"2014","unstructured":"Bodger K, Ormerod C, Shackcloth D, Harrison M, Collaborative IBDC. Development and validation of a rapid, generic measure of disease control from the patient\u2019s perspective: the IBD-control questionnaire. Gut. 2014;63(7):1092\u2013102.","journal-title":"Gut"},{"issue":"5","key":"1610_CR132","doi-asserted-by":"crossref","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE. 2018;13(5):e0195123.","journal-title":"PLoS ONE"},{"issue":"1 Suppl","key":"1610_CR133","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/annrheumdis-2020-eular.5682","volume":"79","author":"B Fautrel","year":"2020","unstructured":"Fautrel B, Bouhnik Y, Desjeux G, Brigui A, Freudensprung U, Addison J. THU0164 PERFUSE: a French prospective\/retrospective non-interventional cohort study of infliximab-naiive and transitioned patients receiving infliximab biosimilar SB2; an interim analysis. Ann Rheum Dis. 2020;79(1 Suppl):297.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1610_CR134","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clinthera.2018.11.002","volume":"41","author":"G Bakalos","year":"2019","unstructured":"Bakalos G, Zintzaras E. Drug discontinuation in studies including a switch from an originator to a biosimilar monoclonal antibody: a systematic literature review. Clin Ther. 2019;41(1):155\u201373.e13.","journal-title":"Clin Ther"},{"issue":"10","key":"1610_CR135","first-page":"952","volume":"24","author":"JS Odinet","year":"2018","unstructured":"Odinet JS, Day CE, Cruz JL, Heindel GA. The biosimilar nocebo effect? A systematic review of double-blinded versus open-label studies. J Manag Care Spec Pharm. 2018;24(10):952\u20139.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"1610_CR136","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734\u201355.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1610_CR137","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1093\/ibd\/izaa128","volume":"26","author":"C Pagnini","year":"2020","unstructured":"Pagnini C, Di Paolo MC, De Angelis G, Torcolacci F, Milano M, Trinca D, et al. Similar but not identical: plaque psoriasis exacerbation in a patient with Crohn\u2019s disease after switching from ct-p13 to sb2 infliximab biosimilar. Inflamm Bowel Dis. 2020;26(8):e83\u20134.","journal-title":"Inflamm Bowel Dis"},{"key":"1610_CR138","first-page":"87","volume":"12","author":"F Cantini","year":"2018","unstructured":"Cantini F, Benucci M. Focus on biosimilar etanercept\u2014bioequivalence and interchangeability. Biologics. 2018;12:87\u201395.","journal-title":"Biologics"},{"issue":"10182","key":"1610_CR139","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","volume":"393","author":"BD Ye","year":"2019","unstructured":"Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393(10182):1699\u2013707.","journal-title":"Lancet"},{"issue":"3","key":"1610_CR140","first-page":"523","volume":"55","author":"A Souto","year":"2016","unstructured":"Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatol (Oxf). 2016;55(3):523\u201334.","journal-title":"Rheumatol (Oxf)"},{"issue":"3","key":"1610_CR141","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40744-019-00169-4","volume":"6","author":"HC Ebbers","year":"2019","unstructured":"Ebbers HC, Pieper B, Issa A, Addison J, Freudensprung U, Rezk MF. Real-world evidence on etanercept biosimilar SB4 in etanercept-naive or switching patients: a systematic review. Rheumatol Ther. 2019;6(3):317\u201338.","journal-title":"Rheumatol Ther."},{"issue":"2","key":"1610_CR142","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","volume":"77","author":"J Kay","year":"2018","unstructured":"Kay J, Schoels MM, Dorner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1610_CR143","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","volume":"54","author":"K Bendtzen","year":"2006","unstructured":"Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54(12):3782\u20139.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1610_CR144","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.2009.112847","volume":"69","author":"GM Bartelds","year":"2010","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010;69(5):817.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1610_CR145","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1080\/14712598.2017.1238454","volume":"16","author":"F Faccin","year":"2016","unstructured":"Faccin F, Tebbey P, Alexander E, Wang X, Cui L, Albuquerque T. The design of clinical trials to support the switching and alternation of biosimilars. Expert Opin Biol Ther. 2016;16(12):1445\u201353.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"1610_CR146","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40259-019-00377-y","volume":"33","author":"E Wolff-Holz","year":"2019","unstructured":"Wolff-Holz E, Tiitso K, Vleminckx C, Weise M. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33(6):621\u201334.","journal-title":"BioDrugs"},{"issue":"5","key":"1610_CR147","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.dld.2019.02.004","volume":"51","author":"G Fiorino","year":"2019","unstructured":"Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, et al. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2019;51(5):632\u20139.","journal-title":"Dig Liver Dis"},{"issue":"11","key":"1610_CR148","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1517\/14712598.2012.711308","volume":"12","author":"HC Ebbers","year":"2012","unstructured":"Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012;12(11):1473\u201385.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"1610_CR149","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10067-018-3982-9","volume":"37","author":"B El Zorkany","year":"2018","unstructured":"El Zorkany B, Al Ani N, Al Emadi S, Al Saleh J, Uthman I, El Dershaby Y, et al. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries. Clin Rheumatol. 2018;37(5):1143\u201352.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1610_CR150","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5114\/reum.2018.77975","volume":"56","author":"P Wiland","year":"2018","unstructured":"Wiland P, Batko B, Brzosko M, Kucharz EJ, Samborski W, Swierkot J, et al. Biosimilar switching\u2014current state of knowledge. Reumatologia. 2018;56(4):234\u201342.","journal-title":"Reumatologia"},{"issue":"4","key":"1610_CR151","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1136\/annrheumdis-2018-214994","volume":"79","author":"J Kay","year":"2020","unstructured":"Kay J, Dorner T, Emery P, Kvien TK, Breedveld FC. Clinical trial and \u201creal-world\u201d data support switching from a bio-originator to its biosimilar. Ann Rheum Dis. 2020;79(4):e44.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1610_CR152","doi-asserted-by":"crossref","first-page":"iv49","DOI":"10.1093\/rheumatology\/kex276","volume":"56","author":"T Uhlig","year":"2017","unstructured":"Uhlig T, Goll GL. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatol (Oxf). 2017;56(4):iv49\u201362.","journal-title":"Rheumatol (Oxf)."},{"issue":"3","key":"1610_CR153","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1515\/acm-2017-0016","volume":"17","author":"R Sutka","year":"2018","unstructured":"Sutka R, Pec J, Pecova T. Biosimilar medicines and patient registries\u2014expectations, limitations, and opportunities. Acta Med Martiniana. 2018;17(3):39\u201351.","journal-title":"Acta Med Martiniana."},{"key":"1610_CR154","first-page":"42","volume":"2017","author":"C Edwards","year":"2017","unstructured":"Edwards C, Hetland ML, Kristensen LE, Cuadrado M. Switching patients from originator to biosimilar medications in rheumatoid arthritis: limiting the \u201cnocebo\u201d effect. Eur Med J. 2017;2017:42\u20138.","journal-title":"Eur Med J."},{"issue":"4 Suppl 78","key":"1610_CR155","first-page":"S28","volume":"31","author":"K Yoshida","year":"2013","unstructured":"Yoshida K, Radner H, Kavanaugh A, Sung YK, Bae SC, Kishimoto M, et al. Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S28\u201332.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01610-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01610-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01610-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T20:23:57Z","timestamp":1699734237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01610-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":155,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1610"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01610-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"14 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"BI, DA, and MM are full-time employees of and own stock or options in Pfizer. NI was a full-time employee of Pfizer at the time the manuscript was developed and owns stock or options in Pfizer. EM received or has pending grants from Roche, Pfizer, Bristol-Myers Squibb and Novartis received honorarium from Eli Lilly, Pfizer, GlaxoSmithKline, Roche, Sanofi, AstraZeneca, Sandoz, Amgen, Gemmene, and AbbVie provided writing assistance, medicines, equipment, or administrative support to Pfizer, AbbVie, and Roche, and received payment for lectures including service on speakers\u2019 bureaus to Eli Lilly, Pfizer, GlaxoSmithKline, Roche, Sanofi, AstraZeneca, Sandoz, Amgen, Gema Biotech, and AbbVie. VFA has received grants to conduct trials on biosimilars from Boehringer Ingelheim, consulting fees related to advisory boards from Pfizer, Amgen, and Sandoz, and payment for lectures provided to Pfizer, Amgen, Sandoz, Celltrion, and Janssen. SD reports consultancy fees from AbbVie, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingleheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc., and Vifor. LP-B served as a speaker, consultant, and advisory member for AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Enterome, Enthera, Ferring, Fresenius Kabi SwissBioSim GmbH, Genentech, Gilead, Hikma, Index Pharmaceuticals, Janssen, Eli Lilly, MSD, Mylan, Nestle, Norgine, Oppilan Pharma, OSE Immunotherapeutics, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Sublimity Therapeutics, Takeda, Tillots, and Vifor, received grants from AbbVie, MSD, and Takeda, and owns stock options from CTMA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"All authors participated in the structuring of this review, contributed to drafting and reviewing the work critically for important intellectual content, and approved the final submitted version.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}